Welcome to our dedicated page for Zimmer Biomet SEC filings (Ticker: ZBH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zimmer Biomet’s filings rarely read like light literature—hundreds of pages detail knee, hip, and S.E.T. sales, FDA clearances, and the cost of bringing robotic surgery to market. Sorting through that volume to spot revenue shifts or a device-recall risk is a real challenge.
Stock Titan solves that problem. Our AI turns dense disclosures into plain language so you can understand Zimmer Biomet SEC documents with AI in minutes, not hours. Need to track Zimmer Biomet insider trading Form 4 transactions? We stream Form 4 insider transactions in real-time and flag unusual executive stock moves. Trying to compare margins across segments? The quarterly earnings report 10-Q filing is summarised automatically, while key trends are highlighted for fast Zimmer Biomet earnings report filing analysis.
You’ll find every form the moment it hits EDGAR—10-K annual report simplified, 8-K material events explained, proxy statement executive compensation breakdowns, and each Zimmer Biomet 8-K material events explained for device launches or recalls. Our platform layers AI-powered summaries, searchable text, and red-line comparisons so you can:
- Monitor Zimmer Biomet executive stock transactions Form 4 before material events
- Follow segment-level revenue trends across knees, hips, and robotics
- Review risk-factor changes without rereading 300 pages
Whether you’re an analyst asking “Where can I find Zimmer Biomet’s quarterly earnings report 10-Q filing?” or a surgeon-investor wondering “How to read Zimmer Biomet’s 10-K annual report”, our exhaustive library keeps you current with real-time updates and expert context. Complex orthopedic disclosures, explained simply.
Zimmer Biomet Holdings, Inc. director Louis Shapiro reported a routine equity-related transaction involving deferred compensation. On 12/31/2025, he acquired 152.22 phantom stock units tied to Zimmer Biomet common stock under the company’s Deferred Compensation Plan for Non-Employee Directors. Each unit is convertible into one share of common stock, and the units are scheduled to be settled in company shares within sixty days after he ceases serving as a director. Following this transaction, he beneficially owned 2,500.354 phantom stock units, which includes 5.625 units previously accrued on 10/31/2025 through the plan’s dividend reinvestment provision.
Zimmer Biomet Holdings, Inc. director Arthur J. Higgins reported changes in his deferred compensation holdings. On 12/31/2025 he acquired 304.439 phantom stock units under the company’s Deferred Compensation Plan for Non-Employee Directors, which are tied 1-for-1 to shares of common stock. These units are scheduled to be settled in cash in ten annual installments after his service as a director ends, beginning within sixty days after the end of the calendar year in which his board service ceases.
Following this transaction, Higgins beneficially owned 35,967.099 phantom stock units. This total includes 85.437 phantom stock units that were previously accrued on October 31, 2025 under the plan’s dividend reinvestment provision.
Zimmer Biomet Holdings, Inc. director Theresa Maria Hilado reported a change in her deferred compensation holdings tied to company stock. On 12/31/2025 she acquired 373.63 phantom stock units under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors at a 1-for-1 conversion rate with common stock. Following this transaction, she beneficially owned 11,275.465 phantom stock units.
The phantom stock units are to be settled in cash in ten annual installments, beginning within sixty days after the end of the calendar year in which her service as a director ends. The reported balance includes 26.117 phantom units accrued on 10/31/2025 through the plan’s dividend reinvestment provision.
Zimmer Biomet Holdings, Inc. director Devdatt Kurdikar reported an equity-related transaction on 12/31/2025 under a deferred compensation arrangement. The filing shows the acquisition of 152.22 phantom stock units at a listed conversion or exercise price of $90.33, bringing his total directly held phantom stock units to 1,769.983.
The units were accrued under the company’s Deferred Compensation Plan for Non-Employee Directors and are designed to be settled in shares of Zimmer Biomet common stock on a 1-for-1 basis within sixty days after he ceases serving as a director. The total includes 3.876 phantom stock units that were added on October 31, 2025 through the plan’s dividend reinvestment provision.
Zimmer Biomet Holdings director reports phantom stock unit grant. On 12/31/2025, a company director acquired 172.977 phantom stock units under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. These units are tied 1-for-1 to shares of Zimmer Biomet common stock and are scheduled to be settled in company shares within sixty days after the director’s service on the board ends. Following this transaction, the director beneficially owned a total of 5,579.523 phantom stock units, which includes 12.952 units accrued on 10/31/2025 through the plan’s dividend reinvestment feature.
Zimmer Biomet Holdings, Inc. reported a director-level deferred compensation transaction involving phantom stock units. On 12/31/2025, a director acquired 304.439 phantom stock units under the company’s Deferred Compensation Plan for Non-Employee Directors at a 1-for-1 ratio with common stock.
After this transaction, the director beneficially owned 31,586.952 phantom stock units in total. These units are to be settled in cash in five annual installments, beginning within sixty days after the end of the calendar year in which the director’s service on the board ends. The total includes 74.943 phantom stock units that were accrued on 10/31/2025 through the plan’s dividend reinvestment feature.
Zimmer Biomet Holdings, Inc. director Michael J. Farrell reported a deferred compensation transaction involving phantom stock units as of 12/31/2025. He acquired 415.144 phantom stock units tied to Zimmer Biomet common stock under the company's Deferred Compensation Plan for Non-Employee Directors at a stated conversion rate of 1-for-1. Each unit represents the economic value of one share, but the units are to be settled in cash, in a lump sum, within sixty days after he ceases serving as a director. Following this transaction, he holds 17,775.682 phantom stock units directly, which includes 41.590 units that were previously accrued on 10/31/2025 through the plan’s dividend reinvestment feature.
Zimmer Biomet Holdings senior vice president and chief human resources officer Lori Winkler reported routine equity compensation activity involving restricted stock units (RSUs) tied to the company’s common stock. On 11/28/2025, RSUs covering 56.534 shares and 122.695 shares were settled into common stock at an exercise price of $0 per share, reflecting previously granted awards becoming deliverable. On the same date, 56.534 shares and 122.695 shares of common stock were withheld at a price of $97.52 per share to cover FICA and related tax obligations associated with her retirement eligibility under the terms of those awards. Following these transactions, she directly holds 6,833 shares of common stock, along with remaining RSUs that vest on March 6, 2026, and in two tranches on February 20, 2026 and February 20, 2027.
Zimmer Biomet Holdings (ZBH) reported an insider equity transaction by its Exec VP & CFO, Suketu Upadhyay. On November 10, 2025, 10,632 performance-based RSUs vested and were converted into common stock at $0 per share. To cover taxes, 4,731 shares were withheld at a price of $87.73 per share.
Following these transactions, the executive’s directly held common stock totaled 54,754 shares. The filing notes these RSUs each represented the right to receive one share of common stock, and the earned performance-based RSUs vested on November 10, 2025.
Zimmer Biomet (ZBH) reported third‑quarter results. Net sales were $2,001.4 million, up from $1,824.2 million. Operating profit rose to $351.3 million from $279.5 million, while net earnings attributable to the company were $230.9 million versus $249.1 million a year ago. Diluted EPS was $1.16 (prior year $1.23). By category, Q3 sales were Knees $792.4 million, Hips $506.2 million, S.E.T. $541.5 million, and Technology & Data, Bone Cement and Surgical $161.3 million.
For the first nine months, net sales reached $5,987.7 million with operating cash flow of $1,179.7 million. The balance sheet showed cash and cash equivalents of $1,292.7 million and long‑term debt of $7,512.6 million as of September 30, 2025. The company completed the Paragon 28 acquisition, paying $1,241.5 million in cash plus contingent consideration fair‑valued at $35.0 million, recording $635.6 million of goodwill. During 2025, Zimmer Biomet issued new senior notes (including $1,748.1 million in U.S. dollar notes and $744.0 million in Swiss Notes) and redeemed $863.0 million of 2025 notes. A quarterly dividend of $0.24 per share was declared.
FAQ
What is the current stock price of Zimmer Biomet (ZBH)?
What is the market cap of Zimmer Biomet (ZBH)?
